Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Solazyme Has a Political Problem

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

This article is part of our Real-Money Stock Picks series.

Alternative energy company Solazyme (Nasdaq: SZYM  ) has a bit of a political problem. Its clean energy reputation has given politically motivated pundits a target that starts with the letters "SOL." Over recent history, critics seem to make frequent -- and in my opinion, unreasonable -- comparisons to bankrupt solar company Solyndra, which failed despite hundreds of millions in taxpayer-funded stimulus support.

The Solyndra comparison crops up frequently as these attention-seekers try to find another poster child for irresponsible government intervention in the marketplace. However, using Solazyme for the sake of this political argument is unfair and overblown.

Reality check
First of all, Solazyme isn't even a solar company. Solazyme produces oils from microalgae.

More important, Solazyme may be a start-up, but what it actually owes to the government pales in comparison to Solyndra's bill. Although Solazyme has received some government funds, there's a huge difference between the $22 million grant Solazyme received in 2009 and the half billion in loan guarantees doled out to Solyndra despite allegations that its existing financial instability was known and failure foreseeable.

Still, the political talkers and commentators like to make a mountain out of a molehill where Solazyme's concerned. One critic railing about government funding for clean energy recently contended that Solazyme relies on a government "lifeline" and implies its financial instability is forcing it to find other uses of its oils beyond clean energy to "survive" because it has been posting annual losses. This strikes me as rhetoric, and a pretty lame argument coming from someone defending a pro-market approach.

Solazyme's doing what any young start-up company should attempt to do: It's seeking out other uses and potential revenue channels for its products. The fact that it's been posting annual losses actually isn't unusual for newly public companies, as dangerous as protracted lack of profitability may be.

Hey, remember (Nasdaq: AMZN  ) ? It wasn't yet profitable when it went public in 1997, nor was there any guarantee it would become the amazing business success it is today (or even succeed, for that matter). Amazon didn't post a quarterly profit until 2002, in fact.

Critics also tend to forget that Solazyme already has some pretty powerful partners in the business world. The company has inked joint development agreements with companies like Dow (NYSE: DOW  ) and Bunge (NYSE: BG  ) , for example, and Chevron (NYSE: CVX  ) produced research funding through June 2012.

As far as ancillary business goes, Solazyme's Algenist skincare line is available in venues like Sephora and J.C. Penney, and the company's looking into uses for its oils as additives in food. It's also repeatedly partnered with Unilever for R&D collaborations into making soap and other products.

Of course, one of the best-known (and most controversial) deals Solazyme has is with the U.S. Navy, through which it received part of a $12 million contract for biofuel.

Solyndra really was SOL
Solazyme's definitely risky, like all innovative start-ups are, but it's no Solyndra. Solyndra filed for an IPO, which it later withdrew, but going public was one of its avenues to the funds it desperately needed. It made a few things clear in its IPO filing, such as how much it needed additional funding for its second manufacturing facility. It also already had substantial debt -- $141 million -- even before the half-billion-dollar loan from the Department of Energy.

Add in the fact that the solar industry overall went into a massive tailspin due to global austerity measures and highly subsidized, low-priced Chinese rivals, and indeed, that's a disaster in the making.

Solazyme may face an uphill battle to bring its products anywhere near mainstream and large volume, but here's another thing to like about the company: It didn't come right out of the gate with a boatload of debt. It owes $17.6 million and has $218.7 million in cash on its balance sheet.

The allegations that some government funding may relate to preferential treatment for some companies over others is certainly distressing and reprehensible. However, while critics contend that Solazyme had ties to an energy advisor that served on President Barack Obama's energy team, Solazyme executives have pointed out that their relationship with the federal government dates back to the Bush Administration.

Fair's fair
I like Solazyme despite the government help, not because of it; I've purchased Solazyme shares twice for the real-money stock portfolio I'm managing for because of its potential to help create a cleaner, greener future. Meanwhile, that relationship is a boon and a risk: If government funding dries up for clean energy, things will become far more difficult for Solazyme and many of its rivals.

Still, Solazyme is an innovative company, and if its efforts are successful, future growth and profits could be huge. Meanwhile, the political chattering class should really leave Solazyme alone unless they're also willing to take on other targets of government handouts they apparently view more warmly. Take big oil, which is extremely well connected politically and enjoys many tax breaks and subsidies that are said to represent between $10 billion and $40 billion annually.

Fair's fair, after all.

Alyce Lomax owns shares of Solazyme in her personal portfolio. The Motley Fool owns shares of and Solazyme. Motley Fool newsletter services have recommended buying shares of and Unilever. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (5) | Recommend This Article (12)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 12, 2012, at 7:49 PM, lanceim59 wrote:

    Anyone who compares Solazyme to Solyndra is just plain ignorant.

  • Report this Comment On June 14, 2012, at 3:46 AM, Cake123xyz wrote:

    Great job, Lomax, for identifying the errant "Sol" association. However, the bigger problem you're overlooking and even partaking in is the errant "clean energy" association. While it's true the company makes clean energy, undoubtedly its focuses have been and will be for many years entirely dependent on higher margin renewable markets such as chemicals and food. While it's sexier to talk about algae fuel, the more practical and profitable arm of Solazyme is its ability to address niche markets such as these in a very innovative way that hasn't been done before.

  • Report this Comment On June 14, 2012, at 3:50 AM, Cake123xyz wrote:

    Out of all the "fools" who've written about Solazyme, you seem to get it the most. Hopefully though you don't miss out on the more important aspect of the company.

    I do say this out of encouragement and don't mean to sound condescending. It is frustrating to me though to see the Motley Fool miss the point with so many authors actually talking about this company. It's only spurring on ignorance.

  • Report this Comment On June 14, 2012, at 4:26 AM, matthewluke wrote:

    It didn't help Solazyme when President Obama mentioned making oil from algae in speech a few months ago. Obviously I wouldn't expect him to discuss the science of it in a political speech. But the way he talked about it, the way he presented it, it made it seem like a big joke. I was already familiar with science behind Solazyme's tailored oils (and other companies' solutions) before the speech, but even I was laughing to myself when he talking about it. That didn't help at all. Not at all.

  • Report this Comment On June 15, 2012, at 1:43 AM, lanceim59 wrote:

    I'll be laughing when this baby becomes a 10+bagger 4 years from now.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1910483, ~/Articles/ArticleHandler.aspx, 10/26/2016 7:15:17 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:00 PM
TVIA $2.60 Down +0.00 +0.00%
TerraVia CAPS Rating: ***
AMZN $822.59 Down -12.59 -1.51% CAPS Rating: ****
BG $61.47 Up +0.02 +0.03%
Bunge CAPS Rating: ***
CVX $101.19 Up +0.42 +0.42%
Chevron CAPS Rating: ****
DOW $53.76 Down -0.35 -0.65%
The Dow Chemical C… CAPS Rating: ****